COGT – cogent biosciences, inc. (US:NASDAQ)
Stock Stats
News
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Cogent Biosciences, Inc. (NASDAQ: COGT) was downgraded by analysts at Needham & Company LLC from a "buy" rating to a "hold" rating.
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Form 8-K Cogent Biosciences, Inc. For: Dec 08
Form SC 13G/A Cogent Biosciences, Inc. Filed by: Point72 Asset Management, L.P.
Form SC 13G/A Cogent Biosciences, Inc. Filed by: Venrock Healthcare Capital Partners II, L.P.
Form SC 13G/A Cogent Biosciences, Inc. Filed by: COMMODORE CAPITAL LP
Form SC 13G/A Cogent Biosciences, Inc. Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.